Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

SCYNEXIS Inc SCYX

SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It develops antifungal platform fungerps, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a range of human fungal pathogens, such as Candida and Aspergillus genera, including multidrug-resistant strains, and Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this novel class of antifungals with additional assets from the fungerp family, including SCY-247, in preclinical stages of development. The United States Food and Drug Administration approved BREXAFEMME for treatment of patients with vulvovaginal candidiasis, also known as vaginal yeast infection, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.


NDAQ:SCYX - Post by User

Comment by dmacdon Apr 22, 2022 4:48pm
133 Views
Post# 34625156

RE:RE:RE:BREXAFEMME - published User side effects

RE:RE:RE:BREXAFEMME - published User side effects I was going to sell at a loss, but decided to lower my average cost due to the discount. They will have $150M cash less Q1 spend. Probably trading at 70% current cash with an approved blockbuster drug in sales mode. New cash is either due to slow sales ramp or accelerated new programs. Management does not care about the SP which means retail will get fleeced more but I am hopeful this might be the end of the incompetent financings. Heads do need to roll here. Mario cannot remain on charge of the business side, and if he expects to then he owes shareholders an explanation, and why do some shareholders get treated differently than others. SEC should investigate Mario since clearly information is being shared with a selective audience.
<< Previous
Bullboard Posts
Next >>